Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Coumarin-type anticoagulant drug vitamin K antagonist with actions similar to those of warfarin that was used for the treatment and prophylaxis of thromboembolic disorders. It works by depressing the hepatic synthesis of vitamin K-dependent coagulation factors.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its high percentage of protein binding make it highly unlikely that significant quantities will pass into breast milk.
No clinical or analytical (coagulation) problems were observed in 125 newborns of mothers treated with dicumarol during the postpartum period. (Brambel 1950)
American Academy of Pediatrics: medication usually compatible with breastfeeding.(AAP 2001)
Due to its unpredictable response and high incidence of gastrointestinal effects, it has been replaced by warfarin and is not marketed today.